Middle East Journal of Cancer

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Forms

Journal Metrics

Assessment of Essential and Non-essential Elements as Risk Evaluation Indices in Men with Prostate Cancer in Calabar South-South Nigeria

Document Type : Original Article(s)

Authors

1 Department of Medical Laboratory Science, University of Calabar, Calabar, Nigeria

2 Department of Chemical Pathology, University of Calabar Teaching Hospital, Calabar, Nigeria

3 Department of Optometry, Imo State University, Owerri, Nigeria

Abstract

Background: Heavy metal (HM) toxicity has been described as a risk factor for the development of prostate disease in men and its assessment could predict susceptibility to prostate cancer (PCa). The current study aimed to assess the levels of HM (selenium [Se], copper [Cu], chromium [Cr] and lead [Pb], iron [Fe], zinc [Zn], magnesium [Mg], and cobalt [Co]) in men with PCa.
Method: 90 men aged 40 to 75 years, including 30 men with PCa, 30 with benign prostatic hyperplasia (BPH), and 30 controls, were recruited in this case-control study. Prostate specific antigen (PSA) was estimated via enzyme linked immunosorbent assay and heavy metals with atomic absorption spectrophotometry. Body mass index (BMI) was also determined.
Results: The men with PCa had significantly higher BMI, PSA, Fe, and Pb and lower Mg, Zn, Cu, and Se compared with the controls. They also had higher PSA, Fe, and Co compared with the BPH (P < 0.05). Those with BPH had higher BMI, PSA, and Fe and lower Mg, Zn, Cu, Se, and Co compared with the controls (P < 0.05). Zn was positively correlated with Mg (r = 0.937, P < 0.001, Cu (r = 0.548, P = 0.002), Se (r = 0.731, P < 0.001), and Co (r=0.733, P < 0.001) only in the men with PCa. Levels of Cu, Mg, and Se were associated with the risk of BPH and PCa.
Conclusion: The men with prostate disease were found to have higher levels of lead and iron and lower magnesium, copper, selenium, and zinc, which necessitate assessment of these elements for early detection of prostate cancer and monitoring the progression of the disease.

Keywords

Full Text

How to cite this article:

Nsonwu-Anyanwu AC, Icha BE, Nsonwu MC, William MI, Emughupogh KT, Opara Usoro CA. Assessment of essential and non-essential elements as risk evaluation indices in men with prostate cancer in Calabar South-South Nigeria. Middle East J Cancer. 2022;13(2):285- 92. doi: 10.30476/mejc.2021. 86638.1361.

References
  1. Jedy-Agba E, Curado MP, Ogunbiyi O, Oga E, Fabowole T, Igbinoba F, et al. Cancer incidence in Nigeria: A report from population-based cancer registries. Cancer Epidemiol. 2012;36: e271–e278.doi.org/10.1016/j.canep.2012.04.007.
  2. Mahmoud AM, Al-Alem U, Dabbous F, Ali MM, Batai K, Shah E, et al. Zinc intake and risk of prostate cancer: Case-control study and meta-analysis. PLoS One. 2016;11(11):e0165956. doi: 10.1371/journal.pone.0165956.
  3. Kaba M, Pirincci N, Yuksel MB, Gecit I, Gunes M, Ozveren H, et al. Serum levels of trace elements in patients with prostate cancer. Asian Pac J Cancer Prev. 2014;15(6):2625-9. doi: 10.7314/apjcp.2014.15.6.2625.
  4. Banas A, Kwiatek WM, Banas K, Gajda M, Pawlicki B, Cichocki T. Correlation of concentrations of selected trace elements with Gleason grade of prostate tissues. J Biol Inorg Chem. 2010;15(7):1147-55. doi:10.1007/s00775-010-0675-5.
  5. Liu Y, Tang M, Zhou Z, Shi H, Lu J. Advances in molecular mechanisms of heavy metal induced cell malignant transformation. Cancer Rep Rev. 2018;2(2):1-4.
  6. IARC: International Agency for Research on Cancer Lyon, France; Monographs on the evaluation of carcinogenic risks to humans, Inorganic and organic lead compounds; 2006, vol. 87. p.134. Available from:http://monographs.iarc.fr/.
  7. Zhanga C, Caia K, Fengb Q, Xua Y, Zhanga Z. Chromium (VI) promotes cell migration through targeting epithelialmesenchymal transition in prostate cancer. Toxicol Lett. 2019; 300: 10-7. doi: 10.1016/j.toxlet.2018.10.012.
  8. Dai Q, Motley SS, Smith JA, Concepcion R, Barocas D, Byerly S, et al. Blood magnesium, and the interaction with calcium, on the risk of high-grade prostate cancer. PLoS One. 2011;6(4):e18237. doi:10.1371/journal.pone.0018237.
  9. Inyengar GR, Subramanian KS, Woittiez JRW. Element analysis of biological samples; Principles and Practice. Chapter 5; Sample decomposition. 1st ed. Boca Raton: CRC Press; 1998.p. 103-35. doi:10.1201/9781003068358.
  10. Stowell LI, Sharman IE, Hamel K. An enzyme-linked immunosorbent assay for prostate-specific antigen. Forensic Sci Intern. 1991;50:125-38. doi: 10.1016/0379-0738(91)90141-5.
  11. Everson ME. Spectrophotometric techniques. In: Burtis, CA; Ashwood, ER, editors. Tietz Textbook of Clinical Chemistry. 2nd ed. Philadelphia: Saunders;1999.p.75-93.
  12. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268-78. doi:10.1038/nrc2351.
  13. Sävblom C, Malm J, Giwercman A, Nilsson JA, Berglund G, Lilja H. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase
    with age. Prostate. 2005;65:66-72. doi.org/10.1002/pros.20254.
  14. Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of black and white Americans. J Urol. 2005;174:872-80. doi: 10.1097/01.ju.0000169262.18000.8a.
  15. Bonn SE, Sjolander A, Tillander A, Wiklund F, Gronberg H, Balter K. Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk. Int J Cancer. 2016;139:50-7. doi:10.18632/oncotarget.11453.
  16. Parikesit D, Mochtar CA, Umbas R, Hamid ARA. The impact of obesity towards prostate diseases.Prostate Int. 2016;4:1-6. doi: 10.1016/j.prnil.2015.08.001.
  17. Printz C. Higher BMI, waist circumference associated with increased risk of aggressive prostate cancer. Cancer. 2016;122(19):2937. doi.org/10.1002/cncr.30335.
  18. Vidal AC, Freedland SJ. Obesity and prostate cancer: A focused update on active surveillance, race, and molecular subtyping. Eur Urol. 2017;72(1):78-83. doi: 10.1016/j.eururo.2016.10.011.
  19. Eken A, Ünlü-Endirlik B, Kaya E, Özgök Y, Erdem O, Akay C. Evaluation of trace element levels in patients with prostate cancer, benign prostatic hyperplasia and chronic prostatitis. Gülhane Týp Derg. 2016;58:27-32. doi: 10.5455/gulhane. 193330.
  20. Peters U, Foster CB, Chatterjee N, Schatzkin A, Reding D, Andriole GL, et al. Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr. 2007;85(1):209-17. doi: 10.1093/ajcn/85.1.209. Erratum in: Am J Clin Nutr. 2007;86(3):808.
  21. Shah S, Minhas U, Khan HA. Trace minerals and heavy metals: Implications in prostate cancer. World Cancer Res. J. 2015;2(4): e625.
  22. Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME. Zinc and human health: an update. Arch Toxicol. 2012;86(4):521-34. doi: 10.1007/s00204-011-0775-1.
  23. Gray MA, Centeno JA, Slaney DP, Ejnik JW, Todorov T, Nacey JN. Environmental exposure to trace elements and prostate cancer in three New Zealand ethnic groups. Int J Environ Res Public Health. 2005;2(3-4):374-84. doi: 10.3390/ijerph2005030001.
  24. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer. 2006;5:17. doi: 10.1186/1476-4598-5-17.
  25. Zaichick V, Zaichick S. Ratios of magnesium/trace element contents in prostate gland as carcinoma’s markers. Cancer Rep Rev. 2017;1(1):1-7. doi: 10.15761/CRR.1000105.
  26. Siddiqui MK, Srivastava S, Mehrotra PK. Environmental exposure to lead as a risk for prostate cancer. Biomed. Environ Sci. 2002;15(4):298-305.
  27. Karimi G, Shahar S, Homayouni N, Rajikan R, Abu Bakar NF, Othman MS. Association between trace element and heavy metal levels in hair and nail with prostate cancer. Asian Pac J Cancer Prev. 2012;13(9):4249-53. doi: 10.7314/apjcp.2012.13.9.4249.
  28. Fukuda H, Ebara M, Yamada H, M, Arimoto M, Okabe S, Obu M, et al. Trace elements and cancer. Japan Med Assoc J. 2004;47(8):391-5.
  29. Vela D. Iron metabolism in prostate cancer; from basic science to new therapeutic strategies. Front Oncol. 2018;8:547. doi: 10.3389/fonc.2018.00547.
  30. Davoodi SH, Jamshidi-Naeini Y, Esmaeili S, Sohrabvandi S, Amir R. The dual nature of iron in relation to cancer: A review. Iran J Cancer Prev. 20169(6):e5494. doi: 10.17795/ijcp-5494.
  31. Yaman M, Atici D, Bakirdere S, Akdeniz I. Comparison of trace metal concentrations in malign and benign human prostate. J Med Chem. 2005;48(2):630-4. doi:10.1021/jm0494568.
  32. D’orta A, Del buono A. Interactions between nutritional and toxic metals: a dietary approach comment to “trace minerals and heavy metals: implications in prostate cancer. World Cancer Res J. 2016; 3(1): e635.
  33. Saleh SAK, Adly HM, Abdelkhaliq AA, Nassir AM. Serum levels of Selenium, Zinc, Copper, Manganese, and Iron in prostate cancer patients. Curr Urol. 2020;14(1):44-9. doi: 10.1159/000499261.
  34. Jedy-Agba E, Curado MP, Ogunbiyi O, Oga E, Fabowole T, Igbinoba F, et al. Cancer incidence in Nigeria: A report from population-based cancer registries. Cancer Epidemiol. 2012;36: e271–e278. doi.org/10.1016/j.canep.2012.04.007.
  35. Mahmoud AM, Al-Alem U, Dabbous F, Ali MM, Batai K, Shah E, et al. Zinc intake and risk of prostate cancer: Case-control study and meta-analysis. PLoS One. 2016;11(11):e0165956. doi: 10.1371/journal.pone.0165956.
  36. Kaba M, Pirincci N, Yuksel MB, Gecit I, Gunes M, Ozveren H, et al. Serum levels of trace elements in patients with prostate cancer. Asian Pac J Cancer Prev. 2014;15(6):2625-9. doi: 10.7314/apjcp.2014.15.6.2625.
  37. Banas A, Kwiatek WM, Banas K, Gajda M, Pawlicki B, Cichocki T. Correlation of concentrations of selected trace elements with Gleason grade of prostate tissues. J Biol Inorg Chem. 2010;15(7):1147-55. doi:10.1007/s00775-010-0675-5.
  38. Liu Y, Tang M, Zhou Z, Shi H, Lu J. Advances in molecular mechanisms of heavy metal induced cell malignant transformation. Cancer Rep Rev. 2018;2(2):1-4.
  39. IARC: International Agency for Research on Cancer Lyon, France; Monographs on the evaluation of carcinogenic risks to humans, Inorganic and organic lead compounds; 2006, vol. 87. p.134. Available from: http://monographs.iarc.fr/.
  40. Zhanga C, Caia K, Fengb Q, Xua Y, Zhanga Z. Chromium (VI) promotes cell migration through targeting epithelialmesenchymal transition in prostate cancer. Toxicol Lett. 2019; 300: 10-7. doi: 10.1016/j.toxlet.2018.10.012.
  41. Dai Q, Motley SS, Smith JA, Concepcion R, Barocas D, Byerly S, et al. Blood magnesium, and the interaction with calcium, on the risk of high-grade prostate cancer. PLoS One. 2011;6(4):e18237. doi:10.1371/journal.pone.0018237.
  42. Inyengar GR, Subramanian KS, Woittiez JRW. Element analysis of biological samples; Principles and Practice. Chapter 5; Sample decomposition. 1st ed. Boca Raton: CRC Press; 1998.p. 103-35. doi:10.1201/9781003068358.
  43. Stowell LI, Sharman IE, Hamel K. An enzyme-linked immunosorbent assay for prostate-specific antigen. Forensic Sci Intern. 1991;50:125-38. doi: 10.1016/0379-0738(91)90141-5.
  44. Everson ME. Spectrophotometric techniques. In: Burtis, CA; Ashwood, ER, editors. Tietz Textbook of Clinical Chemistry. 2nd ed. Philadelphia: Saunders; 1999.p.75-93.
  45. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268-78. doi:10.1038/nrc2351.
  46. Sävblom C, Malm J, Giwercman A, Nilsson JA, Berglund G, Lilja H. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase
    with age. Prostate. 2005;65:66-72. doi.org/10.1002/pros.20254.
  47. Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of black and white Americans. J Urol. 2005;174:872-80. doi: 10.1097/01.ju.0000169262.18000.8a.
  48. Bonn SE, Sjolander A, Tillander A, Wiklund F, Gronberg H, Balter K. Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk. Int J Cancer. 2016;139:50-7. doi:10.18632/oncotarget.11453.
  49. Parikesit D, Mochtar CA, Umbas R, Hamid ARA. The impact of obesity towards prostate diseases. Prostate Int. 2016;4:1-6. doi: 10.1016/j.prnil.
    08.001.
Middle East Journal of Cancer
Volume 13, Issue 2 - Serial Number 50
April 2022
Pages 285-292
Files
Share
How to cite
Statistics